TB-006- a new treatment for Alzheimer’s

3 months ago

Alzheimer’s and Parkinson’s Are Inflammatory Diseases TB-006 targets Galectin-3, a pro-inflammatory protein that activates microglia and accelerates neurodegeneration. By reducing inflammation instead of chasing plaques, TB-006 may restore brain function rather than merely slow decline.
TB-006 Shows Rapid, Real-World Symptom Improvement Patients have demonstrated improvements in memory, clarity, tremors, gait, hallucinations, and nightmares—sometimes within days. Dr. Gale describes the treatment as a true “game changer” with potential symptom reversal.
Expanded Access Is Available—But Patient Selection Matters TB-006 has completed Phase 1 and Phase 2A trials and is currently accessible via FDA Expanded Access. Monthly IV infusions cost approximately $6,300, and about 5% of patients with Galectin-3 mutations may be non-responders, making genetic testing important.

Ed Park, MD

Provided by

Ed Park, MD

William Gael, MD

Guest expert

William Gael, MD

Comments